A period of continued significant progress Avacta Group plc , a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to. | April 25, 2023
Oncology-focussed drugs and diagnostics developer Avacta reported full-year revenue of £9.7m in its preliminary results on Tuesday, up from £2.9m year-on-year.